[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517008":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":171,"collaborators":173,"id":176,"slug":177,"hasResults":178,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":10,"eligibilityCriteria":182,"healthyVolunteers":178,"sex":183,"minAge":10,"maxAge":10,"enrollmentInfo":184,"targetDuration":10,"studyType":187,"phases":10,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},{"fullName":5,"class":6},"Astellas Pharma Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PADCEV",null,"Patients who receive PADCEV Injection 20 mg and 30 mg (enfortumab vedotin) in routine clinical practice according to the drug label approved at the time of marketing authorization.",[13],"Drug: Enfortumab Vedotin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Enfortumab Vedotin","Intravenous",[9],[9,21],"ASG-22CE",[23],{"name":24,"affiliation":25,"role":26},"Central Contact","Astellas Pharma Korea, Inc.","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Astellas Pharma Global Development, Inc.","CONTACT","800-888-7704","astellas.registration@astellas.com",[34,47,56,62,67,77,87,93,99,105,114,123,132,141,147,153,159,165],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":10,"cosmosGeoPoint":41,"geoPoint":46,"contacts":10},"Site KR82001","RECRUITING","Goyang-si","Gyeonggi-do","10408","South Korea",{"type":42,"coordinates":43},"Point",[44,45],126.835,37.65639,{"lat":45,"lon":44},{"facility":48,"status":36,"city":49,"state":38,"zip":50,"country":40,"countryCode":10,"cosmosGeoPoint":51,"geoPoint":55,"contacts":10},"Site KR82012","Suwon","16247",{"type":42,"coordinates":52},[53,54],127.00889,37.29111,{"lat":54,"lon":53},{"facility":57,"status":36,"city":49,"state":38,"zip":58,"country":40,"countryCode":10,"cosmosGeoPoint":59,"geoPoint":61,"contacts":10},"Site KR82008","16500",{"type":42,"coordinates":60},[53,54],{"lat":54,"lon":53},{"facility":63,"status":64,"city":65,"state":65,"zip":66,"country":40,"countryCode":10,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Site KR82007","COMPLETED","Jeollanam-do","58128",{"facility":68,"status":36,"city":69,"state":70,"zip":71,"country":40,"countryCode":10,"cosmosGeoPoint":72,"geoPoint":76,"contacts":10},"Site KR82013","Jeonju","Jeonbuk-do","54907",{"type":42,"coordinates":73},[74,75],127.14889,35.82194,{"lat":75,"lon":74},{"facility":78,"status":79,"city":80,"state":10,"zip":81,"country":40,"countryCode":10,"cosmosGeoPoint":82,"geoPoint":86,"contacts":10},"Site KR82015","ACTIVE_NOT_RECRUITING","Busan","47392",{"type":42,"coordinates":83},[84,85],129.03004,35.10168,{"lat":85,"lon":84},{"facility":88,"status":64,"city":80,"state":10,"zip":89,"country":40,"countryCode":10,"cosmosGeoPoint":90,"geoPoint":92,"contacts":10},"Site KR82010","48108",{"type":42,"coordinates":91},[84,85],{"lat":85,"lon":84},{"facility":94,"status":79,"city":80,"state":10,"zip":95,"country":40,"countryCode":10,"cosmosGeoPoint":96,"geoPoint":98,"contacts":10},"Site KR82009","49201",{"type":42,"coordinates":97},[84,85],{"lat":85,"lon":84},{"facility":100,"status":64,"city":80,"state":10,"zip":101,"country":40,"countryCode":10,"cosmosGeoPoint":102,"geoPoint":104,"contacts":10},"Site KR82016","50612",{"type":42,"coordinates":103},[84,85],{"lat":85,"lon":84},{"facility":106,"status":36,"city":107,"state":10,"zip":108,"country":40,"countryCode":10,"cosmosGeoPoint":109,"geoPoint":113,"contacts":10},"Site KR82014","Daegu","42415",{"type":42,"coordinates":110},[111,112],128.59111,35.87028,{"lat":112,"lon":111},{"facility":115,"status":36,"city":116,"state":10,"zip":117,"country":40,"countryCode":10,"cosmosGeoPoint":118,"geoPoint":122,"contacts":10},"Site KR82018","Daejeon","35365",{"type":42,"coordinates":119},[120,121],127.38493,36.34913,{"lat":121,"lon":120},{"facility":124,"status":79,"city":125,"state":10,"zip":126,"country":40,"countryCode":10,"cosmosGeoPoint":127,"geoPoint":131,"contacts":10},"Site KR82004","Incheon","21565",{"type":42,"coordinates":128},[129,130],126.70515,37.45646,{"lat":130,"lon":129},{"facility":133,"status":36,"city":134,"state":10,"zip":135,"country":40,"countryCode":10,"cosmosGeoPoint":136,"geoPoint":140,"contacts":10},"Site KR82002","Seoul","02841",{"type":42,"coordinates":137},[138,139],126.9784,37.566,{"lat":139,"lon":138},{"facility":142,"status":36,"city":134,"state":10,"zip":143,"country":40,"countryCode":10,"cosmosGeoPoint":144,"geoPoint":146,"contacts":10},"Site KR82005","03181",{"type":42,"coordinates":145},[138,139],{"lat":139,"lon":138},{"facility":148,"status":79,"city":134,"state":10,"zip":149,"country":40,"countryCode":10,"cosmosGeoPoint":150,"geoPoint":152,"contacts":10},"Site KR82003","03722",{"type":42,"coordinates":151},[138,139],{"lat":139,"lon":138},{"facility":154,"status":79,"city":134,"state":10,"zip":155,"country":40,"countryCode":10,"cosmosGeoPoint":156,"geoPoint":158,"contacts":10},"Site KR82017","06351",{"type":42,"coordinates":157},[138,139],{"lat":139,"lon":138},{"facility":160,"status":36,"city":134,"state":10,"zip":161,"country":40,"countryCode":10,"cosmosGeoPoint":162,"geoPoint":164,"contacts":10},"Site KR82006","07417",{"type":42,"coordinates":163},[138,139],{"lat":139,"lon":138},{"facility":166,"status":36,"city":134,"state":10,"zip":167,"country":40,"countryCode":10,"cosmosGeoPoint":168,"geoPoint":170,"contacts":10},"Site KR82011","07985",{"type":42,"coordinates":169},[138,139],{"lat":139,"lon":138},{"type":172,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[174],{"name":175,"class":6},"Seagen Inc.","100517008","a-study-to-survey-adults-in-south-korea-with-cancer-who-receive-padcev-injection-100517008",false,"NCT06011954","A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection","Use-result Surveillance for PADCEV Injection 20 mg and 30 mg (Enfortumab Vedotin) in South Korea","Inclusion Criteria:\n\n* Patients who receive treatment with PADCEV Injection, according to the approved local label.\n\nExclusion Criteria:\n\n* Patients with any contraindication for PADCEV Injection, according to the approved local label.\n* Patients who receive or are going to receive any investigational medicine during the observation period.","ALL",{"count":185,"type":186},202,"ESTIMATED","OBSERVATIONAL","Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer.\n\nPeople in this study will be adults in South Korea with locally advanced or metastatic urothelial cancer. Metastatic means the cancer has spread to other parts of the body. During their care, the person's doctor will have prescribed PADCEV Injection and other medicines to treat their cancer. People in the study will be treated according to their clinic's standard practice. This study is about collecting information only.\n\nThis study will survey people who know they are receiving PADCEV Injection. The aims of the study are to check outcomes of treatment with PADCEV and record any medical problems during the study.\n\nOnce a doctor has prescribed PADCEV Injection, a person in the study will be observed for up to 48 weeks (about 1 year) after their first dose. During this time, a person's medical records will be reviewed to check for any medical problems and to follow the condition of their cancer. If a person in the study stops taking PADCEV Injection sooner than 48 weeks, records will be reviewed until 30 days (1 month) after each person's last dose of PADCEV Injection or until they start a different medicine for their cancer.",[190],"Urothelial Cancer",[190,192,193,9],"Bladder Cancer","enfortumab vedotin","2026-05-13",{"date":196,"type":197},"2026-05-14","ACTUAL",{"date":199,"type":197},"2023-11-01",{"date":201,"type":186},"2027-07-31",{"name":25,"class":6},18]